Germany’s Merck KGaA said this morning that the FDA has placed a partial clinical hold on its multiple sclerosis drug candidate evobrutinib, vying to become a new oral the
Having presented new data at last year’s European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS) Annual Meeting – where the safety and efficacy of Novartis’ Kesimpta (
Biogen's efforts to replenish its multiple sclerosis pipeline have suffered a setback, after the FDA placed a clinical hold on a drug candidate it licensed from China's InnoCare last year f
Ben Hargreaves examines why a research project in the UK could provide key insights to develop treatments against many of the most prominent diseases impacting society.
18 months after it opened an investigation into Teva to see if it illegally blocked generic versions of its big-selling multiple sclerosis drug Copaxone, the European Commission has said it
In a dramatic change in fortunes, Novartis has won a major victory in its bid to defend oral multiple sclerosis therapy Gilenya from early generic competition in the US.
The atrial fibrillation (AFib) detection feature on Apple Watch devices has become the first digital health technology to be qualified under a programme recently introduce
It’s 2024, and in most clinical trials, data is still being moved from the EHR to the EDC manually – with employees reading data from one screen and typing it onto another.